Keeping Pace in Lung Cancer: Guidelines and the Future Direction of Immunotherapy in NSCLC - a podcast by ReachMD

CME credits: 0.25

Valid until: 30-12-2022

Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-guidelines-and-the-future-direction-of-immunotherapy-in-nsclc/13165/

The therapeutic landscape for the first-line treatment of non-driver metastatic NSCLC has become complex and, in some cases, controversial. Based on PD-L1 status, do you know which patients should receive immune checkpoint inhibitor (ICI) monotherapy and when ICI should be combined with chemotherapy? Join Drs. Mark Socinski and Edward Garon as they focus on the intricacies associated with making these therapeutic choices, while also looking at future immunotherapeutic opportunities in the neoadjuvant and adjuvant settings.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD